Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations and Comprehensive Loss

v3.24.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Operating expenses:      
Research and development $ (39,992) $ (17,617) $ (10,712)
General and administrative (7,476) (12,766) (13,825)
Total operating expenses (47,468) (30,383) (24,537)
Operating loss (47,468) (30,383) (24,537)
Interest expense, net (1,428) (2,361) (5,553)
Adjustments to fair value of derivatives 11,056 5,458 (60,964)
Cancellation of share options   (17,350)  
Other income, net 82 503 195
Total other expense / (income) 9,710 (13,750) (66,322)
Loss before income taxes (37,758) (44,133) (90,859)
Income tax expense (613) (301) (705)
Net loss $ (38,371) $ (44,434) $ (91,564)
Net loss per share - basic $ (2.96) $ (3.63) $ (8.41)
Net loss per share - diluted $ (2.96) $ (3.63) $ (8.41)
Weighted average ordinary shares outstanding - basic 12,962,362 12,236,607 10,891,178
Weighted average ordinary shares outstanding - diluted 12,962,362 12,236,607 10,891,178
Statements of Comprehensive Loss      
Net loss $ (38,371) $ (44,434) $ (91,564)
Unrealized income / (loss) on marketable securities 351 (350)  
Comprehensive loss $ (38,020) $ (44,784) $ (91,564)